280 related articles for article (PubMed ID: 21691880)
41. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
42. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
43. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
Madbouly KM; Hussein AM; Abdelzaher E
Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
[TBL] [Abstract][Full Text] [Related]
44. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.
Tokuhara K; Ueyama Y; Nakatani K; Yoshioka K; Kon M
World J Surg Oncol; 2016 Apr; 14():136. PubMed ID: 27129578
[TBL] [Abstract][Full Text] [Related]
45. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
[TBL] [Abstract][Full Text] [Related]
46. Outcome in patients with resectable locally recurrent rectal cancer after total mesorectal excision with and without previous neoadjuvant radiotherapy for the primary rectal tumor.
Alberda WJ; Verhoef C; Nuyttens JJ; Rothbarth J; van Meerten E; de Wilt JH; Burger JW
Ann Surg Oncol; 2014 Feb; 21(2):520-6. PubMed ID: 24121879
[TBL] [Abstract][Full Text] [Related]
47. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
Lin Y; Lin H; Xu Z; Zhou S; Chi P
J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
[No Abstract] [Full Text] [Related]
48. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
49. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
[TBL] [Abstract][Full Text] [Related]
50. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
García-Albéniz X; Gallego R; Hofheinz RD; Fernández-Esparrach G; Ayuso-Colella JR; Bombí JA; Conill C; Cuatrecasas M; Delgado S; Ginés A; Miquel R; Pagés M; Pineda E; Pereira V; Sosa A; Reig O; Victoria I; Feliz L; María de Lacy A; Castells A; Burkholder I; Hochhaus A; Maurel J
World J Gastroenterol; 2014 Nov; 20(42):15820-9. PubMed ID: 25400468
[TBL] [Abstract][Full Text] [Related]
53. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
[TBL] [Abstract][Full Text] [Related]
54. Long-term oncological outcomes of robotic versus laparoscopic total mesorectal excision of mid-low rectal cancer following neoadjuvant chemoradiation therapy.
Lim DR; Bae SU; Hur H; Min BS; Baik SH; Lee KY; Kim NK
Surg Endosc; 2017 Apr; 31(4):1728-1737. PubMed ID: 27631313
[TBL] [Abstract][Full Text] [Related]
55. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision.
Laurent C; Nobili S; Rullier A; Vendrely V; Saric J; Rullier E
J Am Coll Surg; 2006 Nov; 203(5):684-91. PubMed ID: 17084330
[TBL] [Abstract][Full Text] [Related]
56. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Cienfuegos JA; Rotellar F; Baixauli J; Beorlegui C; Sola JJ; Arbea L; Pastor C; Arredondo J; Hernández-Lizoáin JL
Ann Surg Oncol; 2015 Mar; 22(3):916-23. PubMed ID: 25190129
[TBL] [Abstract][Full Text] [Related]
57. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
58. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
59. Delay to Adjuvant Chemotherapy: Survival and Recurrence in Patients of Rectal Cancer Treated with Neo-adjuvant Chemoradiotherapy and Surgery.
Thong DW; Kim J; Naik A; Lu CT; Nolan GJ; Von Papen M
J Gastrointest Cancer; 2020 Sep; 51(3):877-886. PubMed ID: 31691086
[TBL] [Abstract][Full Text] [Related]
60. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
